||PAP Smear Abnormalities
The Pap smear is a common test used to screen women for cervical pre cancer or cancer. Some abnormal Pap smears are not due to cancer, but rather caused by infection or low estrogen levels, while others are early indicators of cancerous growths.
Cervical cells may appear abnormal for a variety of reasons. For example, a woman may have low estrogen levels or a cervical infection, or she may have a precancerous area or various stages of cervical cancer.
A number of medical terms are used to describe abnormalities of the cervix, including:
• Atypical squamous cells of undetermined significance (ASC-US)
• Atypical squamous cells, cannot rule out a high grade lesion (ASC-H)
• Low grade squamous intraepithelial cells (LSIL)
• High grade squamous intraepithelial cells (HSIL)
• Atypical glandular cells (AGC)
• Carcinoma in situ (CIS)
• Invasive cervical cancer
In order to ensure the most sensitive and accurate PAP smear results, Dr. Poliakoff and his staff utilize the state-of-the-art ThinPrep Pap Smear, which is the only liquid-based cytology method approved by the U.S. FDA as "significantly more effective" than the conventional Pap smear for detection of cervical abnormalities.
Follow up Testing:
A Pap smear is only a screening test. Further testing is needed after an abnormal Pap smear to determine whether cervical cancer or a precancerous cervical lesion is present.
Dr. Poliakoff employs the latest technology in diagnosing and treating these conditions and is the only private physician in the U.S. with the LUMA Cervical Imaging System, a breakthrough in non-invasive technology.
LUMA® Cervical Imaging System: Exclusively Available at the Office of Dr. Steven R. Poliakoff, MD
The LUMA® Cervical Imaging System was developed to significantly improve the detection of high-grade precancerous cervical abnormalities that have the potential of becoming invasive cancer. Based on data from the National ALTS study, it is estimated that about 200,000 women with precancerous disease go undiagnosed each year.
LUMA® provides a safe and effective method, that when used as an adjunct to colposcopy, will find at least 26% more high-grade precancerous disease than the gold standard colposcopy in women with ASC and LSIL Pap tests. The office of Steven R. Poliakoff, M.D. the only private practice in the Eastern U.S. currently offering this procedure.
In the U.S. alone, over $6 billion is spent annually on the screening, diagnosis and treatment of women with cervical cancer. Diagnosing cervical cancer is often a long and uncertain process, requiring repeat visits by anxious patients. Approximately four million colposcopy procedures are performed annually, with many repeat exams aimed at arriving at a definitive diagnosis. The U.S. colposcopy market alone is approximately $1 billion annually. The introduction of HPV-DNA testing is expected to be a catalyst for this market, increasing the number of colposcopy procedures performed each year. LUMA offers an unprecedented, reliable, easy-to-use diagnostic exam that provides rapid answers for Dr. Poliakoff and his patients by greatly reducing missed diagnosis and allowing for early-stage decision and treatment of cervical cancer precursors.
Cervical cancer is the sixth most common form of malignancy in U.S. women with 10,000 new cases per year. An additional 600,000 women are identified each year as having pre-invasive cervical cancer. Early detection of these precancerous conditions allows Dr. Poliakoff to treat patients more effectively, less expensively, and with fewer lasting health effects. Currently, women with abnormal Pap tests are diagnosed with a colposcope, a decades-old, low-powered binocular microscope technology, which provides only a limited visual assessment of the cervix. In fact, a recent large-scale National Cancer Institute-sponsored clinical trial demonstrated that colposcopy failed to detect 33% of high-grade precancerous lesions in women referred with questionable Pap results. Dr. Poliakoff's usage of LUMA, in addition to performing colposcopy, gives him the ability to detect close to 30% more ASCUS/LSIL cervical cancer precursors than colposcope alone, an extremely valuable tool in the fight against cervical cancer than colposcopy alone.
More than four million U.S. women have abnormal Pap tests each year, and they typically undergo a series of repeat, stressful and expensive diagnostic tests. For women with precancerous lesions, the long diagnostic cycle can allow the disease to progress and develop into invasive, life-threatening cancers. By providing a more definitive test, LUMA allows Dr. Poliakoff the ability to more effectively manage and treat his patients who are at risk of cervical cancer.
We invite you to call us at 305.596.0870 today for an appointment.